Recent developments focus on clinical trial progress and positive interim data for treatments targeting chronic lower back pain, as well as regulatory clearances and collaborations advancing the company’s stem cell platforms.

• Creative Medical's ADAPT trial for chronic lower back pain showed functional and pain improvements in interim data reported in January 2026 [N1].
• The company reached a major clinical inflection point with positive interim data from the ADAPT trial and CELZ-201 (Olastrocel) treatment for chronic lower back pain [N2].
• Enrollment for the ADAPT trial was completed by December 2025 [N3].
• The company secured FDA clearance for expanded dosing in the back pain trial in March 2025 [N5].
• Creative Medical reported mid-term data indicating reduced opioid use with its StemSpine product [N6].
• CELZ-201 demonstrated 80% efficacy in a Type 2 diabetes trial reported in February 2025 [N7].
• The company expanded its AI collaboration with Greenstone Biosciences to advance the IPSCelz platform in February 2025 [N8].

The company has demonstrated progress in clinical development, including positive interim data from the ADAPT trial for chronic lower back pain and efficacy signals in Type 2 diabetes trials. FDA clearance for expanded dosing in back pain trials and collaborations to advance its IPSCelz platform using AI indicate active development and innovation. Strong liquidity ratios provide financial flexibility to support ongoing research and development. The company’s proprietary stem cell technologies and expanding intellectual property portfolio could enable entry into multiple therapeutic markets.

The company reports minimal revenue and significant net losses, reflecting ongoing investment in research and development without current commercial scale. The biotechnology sector’s rapid technological changes and competitive landscape pose risks to product relevance and market acceptance. Limited capital resources and experience in marketing and sales may constrain commercialization efforts. Clinical trial outcomes remain uncertain, and regulatory hurdles could delay or prevent product approvals. External factors such as supply chain disruptions and geopolitical conflicts may adversely impact operations.

Creative Medical’s moat is based on its proprietary stem cell technologies and intellectual property portfolio, including patents related to autologous stem cell concentration kits and reprogrammed immune cell therapies. The company’s focus on novel biological therapeutics in multiple therapeutic areas, combined with ongoing clinical trials and FDA clearances, provides a foundation for potential differentiation. However, the biotechnology industry is highly competitive and rapidly evolving, with many companies possessing greater resources and established market presence. The company’s moat is thus dependent on successful clinical development, regulatory approvals, and commercialization of its therapies and products.

• Technological and Market Risks: Rapid changes in technology and customer demands may render the company’s products obsolete or unmarketable. The company must adapt to advances and develop new or enhanced products timely and cost-effectively.
• Financial and Capital Risks: The company has limited capital resources which may restrict its ability to fund research, development, and commercialization activities. Continued net losses and minimal revenue highlight financial challenges.
• Clinical and Regulatory Risks: Clinical trial outcomes are uncertain and regulatory approvals are required for commercialization. Delays or failures in trials or regulatory processes could impact business prospects.
• Competitive Risks: The company competes with firms having substantially greater resources and established marketing and sales capabilities, which may limit its market penetration and growth.
• Operational Risks: Supply chain disruptions and geopolitical conflicts may adversely affect the company’s operations and financial results.

• Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company focused on novel biological therapeutics in immunotherapy, endocrinology, urology, neurology, and orthopedics [S1].
• The company operates primarily through its subsidiary Creative Medical Technologies, Inc. (CMT), which markets and sells disposable stem cell concentration kits (CaverStem® and FemCelz®) used by physicians for autologous procedures treating erectile dysfunction and female sexual dysfunction [S1].
• The company has expanded its development and acquisition of intellectual property to include therapeutic treatments using reprogrammed stem cells for neurologic disorders, lower back pain, Type-1 diabetes, and other diseases through subsidiaries ImmCelz, Inc., StemSpine, Inc., and AlloCelz LLC; however, ImmCelz and AlloCelz have not commenced commercial activities [S1].
• ImmCelz platform (CELZ-100) involves reprogramming a patient's own extracted immune cells outside the body to endow regenerative properties, with the immune cells being smaller than stem cells and believed to penetrate damaged tissues more effectively [S1].
• The company manages its operations as one reportable segment, with the Chief Executive Officer as the Chief Operating Decision Maker [S1].
• Revenue is generated from the sale of disposable stem cell concentration kits, recognized upon delivery to customers, with deferred revenue reported when earnings process is incomplete [S2].
• As of December 31, 2025, the company reported $7,399,014 in current assets and $284,880 in current liabilities, resulting in a current ratio of approximately 25.97 and a cash ratio of 15.82, indicating strong liquidity [S1].
• For the fiscal year ended December 31, 2025, the company reported revenue of $6,000 and a net loss of $5,995,008, with diluted EPS of -2.52 USD per share [S1].
• The company has ongoing clinical trials including the ADAPT trial for chronic lower back pain using CELZ-201 (Olastrocel), which reached a major clinical inflection point with positive interim data reported in January 2026 [N2][N1].
• Enrollment for the ADAPT trial was completed by December 2025 [N3].
• The company secured FDA clearance for expanded dosing in the back pain trial in March 2025 [N5].
• The company reported mid-term data showing reduced opioid use with its StemSpine product [N6].
• CELZ-201 showed 80% efficacy in a Type 2 diabetes trial reported in February 2025 [N7].
• The company expanded its AI collaboration with Greenstone Biosciences to advance the IPSCelz platform in February 2025 [N8].
• The company has a board of directors and named executive officers with disclosed compensation and stock option grants [S1].
• The company has adopted a Code of Business Conduct and Ethics and an insider trading policy applicable to directors, officers, and employees [S1].
• The company had 3,696,668 shares outstanding as of March 20, 2026 [S1].
• Recent news coverage highlights functional and pain improvements in the ADAPT trial for chronic lower back pain [N1].
• The company has reported early success in the CELZ-201-DDT trial for back pain [N1].
• The company’s marketing and sales efforts are limited by capital and experience, and it faces competition from companies with greater resources [S1].
• The industry is characterized by rapid technological change and customer demand shifts, which may render products obsolete or unmarketable [S1].
• The company’s future success depends on adapting to technological advances, developing new products, and enhancing current offerings in a timely and cost-effective manner [S1].
• The company may face technical difficulties delaying product development or marketing, and may lack capital to further develop existing or new products [S1].
• Global supply chain disruptions and geopolitical conflicts may adversely affect the company’s operations [S1].